Second Malignancies in High‑Dose Areas of Previous Tumor Radiotherapy

Abstract

The 5- and 15-year probability to develop a histopathologically independent second tumor in or near the irradiated first tumor site, i.e., after intermediate or high radiation doses, was 0.5% and 2.2%, respectively. To identify potentially radiogenic second malignancies, a follow-up far beyond 5 years is mandatory. The incidence and potential dose-response relationship intermediate will be analyzed by a case-case and a case-control study of the Ulm data.

Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry

“…These low doses have been questioned as an inductor of second cancers. [45][46][47] However, this risk remains relative in patients with other risk factors for cancer and because of the low life expectancy of these patients (regardless of the localization and stage). However, we have already shown that the integral dose was not increased by the use of tomotherapy IMRT.…”

Biologische Mechanismen der Strahlenwirkung

“…werden. Die Zeit bis zu deren klinischer Manifestation kann mitunter ebenfalls mehrere Jahrzehnte betragen [10,15,23,24]. Betreffen diese Mutationen Keimzellen, können genetisch bedingte Verände-rungen bei den Nachkommen auftreten; sog.…”

ABVD vs. radiotherapy in early stage Hodgkin’s lymphoma

“…None of the 4 SC in the radiation-only cohort with favorable risk (2 lymphoma, cervical cancer and melanoma) was typical for the used RT fields (although a detailed location of the lymphomas and the melanoma were not given). Recent studies on patients with various cancers that received high-dose radiation therapy revealed a 2.2 % (dose-dependent) probability of developing a second cancer in the irradiated field [19] and analyses of the SEER registry revealed that an estimated 8% of SC developing in patients are attributable to radiation treatment for the original cancer [20].…”